Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Settings
Language
ENGLISH
Currency
USD
Theme
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rank in Stocks #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Share Price
$0.94180721
Market Cap
$22.26M
Change (1 day)
0.38%
Change (1 year)
-14.35%
Country
FR
Trade Valbiotis SA (ALVAL)

Category

Healthcare
Revenue for Valbiotis SA (ALVAL)
Revenue in Dec 2025 TTM: $1.06M
According to Valbiotis SA latest financial reports the company's current revenue (TTM) is $1.06M. In 2023 the company made a revenue of $5.23M an increase over the revenue in the year 2022 that was $842.05K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Valbiotis SA from 2015 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $1.06M 483.09%
2024 $182.10K -96.52%
2023 $5.23M 521.36%
2022 $842.05K 148.49%
2021 $338.87K -91.00%
2020 $3.77M 3,588.18%
2019 $102.10K 12.47%
2018 $90.78K 2,421.95%
2017 $3.60K -99.47%
2016 $679.71K 6,159.87%
2015 $10.86K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 4,901,516.93%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 1,154,073.15%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 1,405,013.12%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 855,259.12%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $4.94B 465,536.55%
NL